guest ::
| Home > Publications Database > Consensus guidelines for the monitoring and management of metachromatic leukodystrophy in the United States. > print |
| Home > Publications Database > Consensus guidelines for the monitoring and management of metachromatic leukodystrophy in the United States. > print |
| 001 | 270681 | ||
| 005 | 20250127091757.0 | ||
| 024 | 7 | _ | |a pmc:PMC11348704 |2 pmc |
| 024 | 7 | _ | |a 10.1016/j.jcyt.2024.03.487 |2 doi |
| 024 | 7 | _ | |a pmid:38613540 |2 pmid |
| 024 | 7 | _ | |a 1465-3249 |2 ISSN |
| 024 | 7 | _ | |a 1477-2566 |2 ISSN |
| 024 | 7 | _ | |a altmetric:161540435 |2 altmetric |
| 037 | _ | _ | |a DZNE-2024-00853 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Adang, Laura A |b 0 |
| 245 | _ | _ | |a Consensus guidelines for the monitoring and management of metachromatic leukodystrophy in the United States. |
| 260 | _ | _ | |a Abingdon |c 2024 |b Taylor & Francis Group |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1721815927_7926 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Metachromatic leukodystrophy (MLD) is a fatal, progressive neurodegenerative disorder caused by biallelic pathogenic mutations in the ARSA (Arylsulfatase A) gene. With the advent of presymptomatic diagnosis and the availability of therapies with a narrow window for intervention, it is critical to define a standardized approach to diagnosis, presymptomatic monitoring, and clinical care. To meet the needs of the MLD community, a panel of MLD experts was established to develop disease-specific guidelines based on healthcare resources in the United States. This group developed a consensus opinion for best-practice recommendations, as follows: (i) Diagnosis should include both genetic and biochemical testing; (ii) Early diagnosis and treatment for MLD is associated with improved clinical outcomes; (iii) The panel supported the development of newborn screening to accelerate the time to diagnosis and treatment; (iv) Clinical management of MLD should include specialists familiar with the disease who are able to follow patients longitudinally; (v) In early onset MLD, including late infantile and early juvenile subtypes, ex vivo gene therapy should be considered for presymptomatic patients where available; (vi) In late-onset MLD, including late juvenile and adult subtypes, hematopoietic cell transplant (HCT) should be considered for patients with no or minimal disease involvement. This document summarizes current guidance on the presymptomatic monitoring of children affected by MLD as well as the clinical management of symptomatic patients. Future data-driven evidence and evolution of these recommendations will be important to stratify clinical treatment options and improve clinical care. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a gene therapy |2 Other |
| 650 | _ | 7 | |a leukodystrophy |2 Other |
| 650 | _ | 7 | |a metachromatic leukodystrophy |2 Other |
| 650 | _ | 7 | |a newborn screening |2 Other |
| 650 | _ | 7 | |a transplant |2 Other |
| 650 | _ | 7 | |a Cerebroside-Sulfatase |0 EC 3.1.6.8 |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Infant, Newborn |2 MeSH |
| 650 | _ | 2 | |a Cerebroside-Sulfatase: genetics |2 MeSH |
| 650 | _ | 2 | |a Consensus |2 MeSH |
| 650 | _ | 2 | |a Genetic Therapy: methods |2 MeSH |
| 650 | _ | 2 | |a Leukodystrophy, Metachromatic: therapy |2 MeSH |
| 650 | _ | 2 | |a Leukodystrophy, Metachromatic: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Leukodystrophy, Metachromatic: genetics |2 MeSH |
| 650 | _ | 2 | |a Neonatal Screening: methods |2 MeSH |
| 650 | _ | 2 | |a United States |2 MeSH |
| 700 | 1 | _ | |a Bonkowsky, Joshua L |b 1 |
| 700 | 1 | _ | |a Boelens, Jaap Jan |b 2 |
| 700 | 1 | _ | |a Mallack, Eric |b 3 |
| 700 | 1 | _ | |a Ahrens-Nicklas, Rebecca |b 4 |
| 700 | 1 | _ | |a Bernat, John A |b 5 |
| 700 | 1 | _ | |a Bley, Annette |b 6 |
| 700 | 1 | _ | |a Burton, Barbara |b 7 |
| 700 | 1 | _ | |a Darling, Alejandra |b 8 |
| 700 | 1 | _ | |a Eichler, Florian |b 9 |
| 700 | 1 | _ | |a Eklund, Erik |b 10 |
| 700 | 1 | _ | |a Emrick, Lisa |b 11 |
| 700 | 1 | _ | |a Escolar, Maria |b 12 |
| 700 | 1 | _ | |a Fatemi, Ali |b 13 |
| 700 | 1 | _ | |a Fraser, Jamie L |b 14 |
| 700 | 1 | _ | |a Gaviglio, Amy |b 15 |
| 700 | 1 | _ | |a Keller, Stephanie |b 16 |
| 700 | 1 | _ | |a Patterson, Marc C |b 17 |
| 700 | 1 | _ | |a Orchard, Paul |b 18 |
| 700 | 1 | _ | |a Orthmann-Murphy, Jennifer |b 19 |
| 700 | 1 | _ | |a Santoro, Jonathan D |b 20 |
| 700 | 1 | _ | |a Schöls, Ludger |0 P:(DE-2719)2810795 |b 21 |u dzne |
| 700 | 1 | _ | |a Sevin, Caroline |b 22 |
| 700 | 1 | _ | |a Srivastava, Isha N |b 23 |
| 700 | 1 | _ | |a Rajan, Deepa |b 24 |
| 700 | 1 | _ | |a Rubin, Jennifer P |b 25 |
| 700 | 1 | _ | |a Van Haren, Keith |b 26 |
| 700 | 1 | _ | |a Wasserstein, Melissa |b 27 |
| 700 | 1 | _ | |a Zerem, Ayelet |b 28 |
| 700 | 1 | _ | |a Fumagalli, Francesca |b 29 |
| 700 | 1 | _ | |a Laugwitz, Lucia |b 30 |
| 700 | 1 | _ | |a Vanderver, Adeline |b 31 |
| 773 | _ | _ | |a 10.1016/j.jcyt.2024.03.487 |g Vol. 26, no. 7, p. 739 - 748 |0 PERI:(DE-600)2071176-1 |n 7 |p 739 - 748 |t Cytotherapy |v 26 |y 2024 |x 1465-3249 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/270681/files/DZNE-2024-00853_Restricted.pdf |
| 856 | 4 | _ | |u https://pub.dzne.de/record/270681/files/DZNE-2024-00853_Restricted.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |o oai:pub.dzne.de:270681 |p VDB |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 21 |6 P:(DE-2719)2810795 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-24 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CYTOTHERAPY : 2022 |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-24 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-24 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-24 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-10-24 |
| 920 | 1 | _ | |0 I:(DE-2719)5000005 |k AG Schöls |l Clinical Neurogenetics |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)5000005 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|